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Background: Adiponectin, an adipokine facilitating insulin action, has antiatherogenic effects. This study
investigated whether common single nucleotide polymorphisms (SNPs) in the adiponectin gene influenced plasma
adiponectin level and whether they were associated with the risk of coronary artery disease (CAD) and its
angiographical severity in type 2 diabetes in Chinese population.
Methods: 11 tagging SNPs were genotyped in 1110 subjects with or without CAD in type 2 diabetes. Variants of
adiponectin gene were determined by Taqman polymerase chain reaction method. The plasma adiponectin
concentrations were measured by sandwich enzyme-linked immunosorbent assay. The severity and extent of
coronary atherosclerosis were assessed using the angiographic Gensini score and Sullivan Extent score.
Results: Among the 11 SNPs, the minor G allele of SNP rs266729 was significantly associated with higher odds of
CAD (odds ratio (95% CI) = 1.49 (1.10 - 2.16), P = 0.022) after adjusting for covariates. In stepwise multivariate
logistic regression, SNP rs266729 was a significant independent factor of CAD. Multivariate linear regression analysis
revealed that rs266729 (β = −0.101, P < 0.0001), rs182052 (β = −0.044, P = 0.0035), and rs1501299 (β = 0.073,
P < 0.0001) were significantly associated with adiponectin level, and also indicated that the minor G allele of SNP
rs266729 had higher Gensini score (β = 0.139, P < 0.001) and Sullivan Extent score (β = 0.107, P < 0.001).
Haplotypes analysis revealed different haplotype distributions in case and control subjects (P = 0.0003), with two
common haplotypes GGG and GAG of the rs266729, rs182052, and rs1501299 being associated in heterozygotes
with a greater than threefold increase in cardiovascular risk (odds ratio (95% CI)=3.39 (1.83 - 6.30), P = 0.0001).
Conclusions: In our population, genetic variants in the adiponectin gene influence plasma adiponectin levels, and
one of them is a strong determinant of CAD susceptibility and its angiographical severity in type 2 diabetes. This
study has provided further evidence for a role of adiponectin in the development of CAD.
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Adiponectin is an adipose tissue-derived adipocytokine
protein, which has been identified in the human adipose
tissue complementary DNA library [1]. Concentration of
adiponectin decreases in patients with the phenotypes of
the metabolic syndrome [2], including obesity [3], type-2
diabetes [4], insulin resistance [5], hypertension [6].
Lower plasma concentrations of adiponectin are also
associated with coronary artery disease (CAD) [7,8].
In humans, adiponectin is encoded by portions of
exons 2 and 3 among the three exons of the adiponectin,
C1Q and collagen domain-containing (ADIPOQ) gene
located on chromosome 3q27 [9]. The role of common
polymorphisms of the adiponectin gene in cardiovascu-
lar disease has been investigated previously in several
populations, such as Caucasian and Korean population
[10,11]. However, inconsistent findings on the asso-
ciation of several genetic variants of ADIPOQ with
adiponectin level [12-15] and cardiovascular disease have
been reported [16,17], which could be due to a differ-
ence in ethnic populations, single nucleotide polymor-
phism (SNP) selection, and study power. Therefore, data
regarding the relationship between adiponectin gene
polymorphisms and CAD need to be further investigated
because of the conflicting reported results. To our best
knowledge, there is no systematic analysis of SNPs in
ADIPOQ gene with regard to both adiponectin level and
CAD in Chinese population.
In this study, we investigated the association of common
genetic variants in the ADIPOQ gene with adiponectin
level and CAD in type 2 diabetes, a condition of accelerated
atherogenesis in which the presence of defects in contribut-
ing genetic factors may be especially evident, and we also
investigated its association with angiographical severity of
coronary atherosclerosis.Materials and methods
Patients and controls
Consecutive 560 stable CAD patients and 550 control
subjects with type 2 diabetes were recruited from the
inpatients or outpatients who have undergone coronary
arteriography for suspected or known coronary athero-
sclerosis at our hospital. The criteria for CAD were a
≥50% organic stenosis of at least one segment of a major
coronary artery or their main branches confirmed by
coronary angiography. Control subjects were the patients,
aged ≥55 years, who had diabetes for ≥5 years, with coron-
ary stenosis (at angiography) <50%. Exclusion criteria were
active inflammatory conditions, autoimmune disease, ma-
lignancies, use of immunosuppressive drugs and known
hematological disorders. Patients with ST elevation myocar-
dial infarction, unstable angina or NSTEMI were also ex-
cluded. Written informed consent was obtained from allenrolled participants and this study was approved by the
local Ethics Committee.
Coronary angiography and image interpretation
Coronary angiography was carried out according to the
Judkins technique. Coronary artery stenoses were im-
aged in the centre of the field from multiple projections.
An overlap of side branches and foreshortening of rele-
vant coronary arteries was avoided as far as possible.
Coronary angiograms were scored according to Gensini
score and Sullivan Extent score.
In Gensini’s scoring system [18], angiographic stenosis
in the range of 0%–25% was scored as 1 point, stenosis
in the range of 25%–50% was scored as 2 points, 50%–
75% was scored as 4 points, 75%–90% was scored as 8
points, 90%–99% was scored as 16 points, and total oc-
clusion was scored as 32 points. Each stenosed segment
was then weighted from 0.5 to 5, depending on the func-
tional significance of the area supplied by that segment.
These scores were multiplied by the coefficient defined
for each coronary artery and segment, and the results
were then summed.
The Sullivan Extent score quantifies the percentage of
the coronary intimal surface area affected by atheroma,
as identified by lumen irregularity, was multiplied by a
factor for each vessel: left main, 5; left anterior descend-
ing, 20; main diagonal branch, 10; first septal perforator,
5; left circumflex, obtuse marginal, and posterolateral
vessels, 10; right coronary, 20; and main posterior de-
scending branch, 10. When the major lateral wall branch
was a large obtuse marginal or intermediate vessel, the
factor used was 20, with factor of 10 for the left circum-
flex. Occluded vessels which were filled with contrast
medium by collateral flow were evaluated according to
the visible irregularities of the vessel wall. If no collateral
flow existed, the mean value of all the other vessel segments
in this angiogram was transferred to this occluded vessel
segment [19].
The scores were independently assessed by two experi-
enced interventional cardiologists who were blinded to
the procedural data and clinical outcomes. The κ for
inter-observer variability that was used to estimate the
Gensini score and Sullivan Extent score was 0.88, 0.83,
respectively, whereas the κ for intra-observer variability
was 0.92, 0.90, respectively. In cases of disagreement
regarding the Gensini score or Sullivan Extent score, the
average of the values from the 2 readers was used as the
final value.
Assessment of covariates, plasma adiponectin, and other
biomarkers
Main clinical data including age, sex, body mass index
(BMI, were calculated as weight in kilograms divided by the
square of height in meters), current smoking (defined as at
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diabetes duration, treatment methods of diabetes were
recorded. Fast Blood samples were collected from CAD
patients and control subjects, and were stored at −80°C at
the day of collection. High-density lipoprotein (HDL)
cholesterol, low-density lipoprotein (LDL) cholesterol, tri-
glyceride, glucose, and hemoglobin A1c (HbA1c) were de-
termined. The plasma adiponectin concentration was
measured by a commercially available sandwich enzyme-
linked immunosorbent assay (Adiponectin ELISA Kit,
Otsuka Pharmaceutical Co.Ltd., Tokushima, Japan), the
employed assay exhibited inter- and intra-assay CV’s of
3.8–6.5%, depending on the adiponectin concentration of
the assayed material. The lower limit of detection was
0.036 μg/ml.
Determination of adiponectin genotypes
Genomic DNA was extracted from EDTA blood using the
E.Z.N.A. W Blood DNA Mini kit (PEQLAB Biotechnologie
Ltd., Erlangen, Germany). Tagging SNPs were selected in
the ADIPOQ gene from the HapMap Han Chinese popula-
tion (HapMap Data Rel 24/phase II, NCBI build 36). There
were 11 tagging SNPs (rs266729, rs182052, rs16861205,
rs822396, rs12495941, rs7627128, rs1501299, rs3821799,
rs3774262, rs1063539, rs12629945), which captured all the
21 SNPs from 1-kb region upstream to 1-kb downstream
of the gene [GenBank accession number: NC_000003]
with r2 > 0.8 and minor allele frequency (MAF) > 0.05.
Genotypings were carried out by the 5′ nuclease assay
using TaqManW MGB probes on an ABI PrismW 7000
Sequence Detection System (Applied Biosystems, Forster
City, CA, USA). TaqManW MGB probes were allele-
specifically labeled with FAM™ and VIC™ reporter dyes, re-
spectively and provided together with corresponding PCR
primers by the Assay-on-demand™ service (Applied
Biosystems) as a 20 × primer/probe mix. The 5′ nuclease
assay was performed in a 15-μL volume, comprising 30–
100 ng genomic DNA, 1 × TaqManW Universal PCR
Master Mix (Applied Biosystems), and 1 × primer/probe
mix under the following amplification conditions: 2 min
at 55°C, 10 min at 95°C and 35 cycles at 90°C for 30 s
and 60°C for 1 min. After measurement of the allele-
specific fluorescence, SDS software (version 1.1) was
used for allelic discrimination. Genotyping quality was
tested by including six blinded duplicate samples in
each 96-well assay. The average agreement rate of dupli-
cate samples was > 99%.
Statistical analyses
Continuous variables with normal distribution were
expressed as mean ± SD, means were compared by un-
paired Student’s t-test. Variables with skewed distribu-
tions were ln-transformed before analysis. Categorical
variables were presented as percentages and wereanalyzed by Chi-squared test. Genotype distributions
were tested at each polymorphic locus for departure
from Hardy-Weinberg equilibrium. Haploview version
4.2 was used to assess linkage disequilibrium (LD).
Haplotype frequency and haplotype-tagging SNPs were
also determined by means of the algorithms
implemented in the Haploview software [20], using 0.05
as the frequency threshold to define common haplo-
types. Multivariate logistic or linear regression models
were used to estimate the odds ratios (ORs) or regres-
sion coefficients under the assumption of an additive ef-
fect of allele dosage. Correction for multiple testing was
performed by the SNP spectral decomposition method
(SNPSpD) [21]. Under this method, the effective number
of independent marker loci (MeffLi) was 7.5, and the
experimental-wide significance threshold to keep type 1
error rate at 5% was 0.0086. Correction for testing of
multiple phenotypes was not performed when the phe-
notypes tested were closely related to each other. The P
values for interaction were estimated by adjusting for
the main effects of all covariates (age, sex, BMI, diabetes
duration, current smoking, hypertension, HbA1c, fasting
glucose, 2-h post-OGTT glucose, triglyceride, HDL chol-
esterol, LDL cholesterol) in the multivariate regression
models.
Maximum likelihood estimates of haplotype frequencies
in CAD patients and control subjects were derived using
the expectation-maximization algorithm as implemented in
the function HAPLO.EM of the Haplo Stats suite [22]. The
association between CAD and common (≥ 0.05) ADIPOQ
haplotypes was analyzed using the score statistics proposed
by Schaid et al. [22], and implemented in the function
HAPLO.SCORE of the Haplo Stats software. This method
allows adjustment for covariates (age, sex, BMI, diabetes
duration, current smoking, hypertension, HbA1c, triglycer-
ide, HDL cholesterol, LDL cholesterol) and provides a glo-
bal test of association, as well as haplotype-specific tests.
After testing for association with haplotypes, a combination
of haplotypes (i.e., a diplotype) was assigned to each indi-
vidual on the basis of the posterior probabilities of the
different phases. The risk of CAD associated with each
diplotype relative to CAG/CAG homozygotes was then
estimated by multivariate logistic regression analysis as de-
scribed above. Statistical significances were considered
significant at P < 0.05. The SPSS statistical software package
ver.16.0 was used for statistical analysis.Results
Subject characteristics and genotyping
Clinical characteristics of the CAD patients and control
subjects are listed in Table 1. CAD patients had worse
cardiovascular risk profile, longer diabetes duration,
worse glycemic control and lower plasma adiponectin
Table 1 Clinical characteristics of control subjects and CAD patients with type 2 diabetes
Control Subjects CAD Patients P value
n 550 560
Age (years) 61.1 ± 7.9 66.0 ± 6.9 < 0.001
Male subjects (%) 42.5 55.4 < 0.001
BMI (kg/m2) 22.0 ± 3.4 24.3 ± 3.9 < 0.001
Diabetes duration (years) 10.8 ± 3.6 12.0 ± 4.4 < 0.001
Current smoking (%) 32.0 38.4 0.026
Hypertension (%) 61.8 68.9 0.013
Fasting glucose (mmol/l) 6.49 ± 2.71 6.86 ± 3.10 0.038
2-h post-OGTT glucose (mmol/l) 7.57 ± 1.21 8.40 ± 2.07 < 0.001
HbA1c (%) 7.18 ± 1.01 7.53 ± 1.22 < 0.001
Triglyceride (mmol/l) 1.46 ± 0.21 1.49 ± 0.26 0.023
HDL cholesterol (mmol/l) 1.33 ± 0.28 1.23 ± 0.22 < 0.001
LDL cholesterol (mmol/l) 3.18 ± 0.84 3.25 ± 0.83 0.135
Adiponectin (μg/ml) 7.11 (6.90 - 7.33) 5.90 (5.69 - 6.12) < 0.001
Gensini score 13.4 (12.6 - 14.2) 22.5 (21.1 - 24.1) < 0.001
Sullivan Extent score 15.9 (13.9 - 16.6) 28.7 (25.5 - 31.1) < 0.001
Treatment
Diet only (%) 11.3 11.4 0.935
Oral agents (%) 57.6 53.2 0.138
Insulin (%) 31.1 35.4 0.131
Data are expressed as mean ± SD or geometric mean (95% confidence interval). BMI = body mass index; CAD = coronary artery disease; HbA1c = hemoglobin
A1C; HDL cholesterol = high-density lipoprotein cholesterol; LDL cholesterol = low-density lipoprotein cholesterol.
Tong et al. Cardiovascular Diabetology 2013, 12:67 Page 4 of 10
http://www.cardiab.com/content/12/1/67level (P < 0.001) than the control subjects. The two
groups were similar with respect to LDL cholesterol
level and treatments of diabetes.
Among the 11 SNPs genotyped, the genotype frequencies
for SNPs did not differ significantly from those expected
under Hardy–Weinberg equilibrium. There were four SNP






rs266729 C : G 0.240
rs182052 G : A 0.411
rs16861205 G : A 0.158
rs822396 A : G 0.126
rs12495941 G : T 0.372
rs7627128 C : A 0.238
rs1501299 G : T 0.256
rs3821799 T : C 0.392
rs3774262 G : A 0.288
rs1063539 G : C 0.285
rs12629945 G : A 0.198
MAF, minor allele frequency. All OR and P values are adjusted for age and sex. *P vrs7627128, rs3821799 and rs3774262, rs3821799 and
rs1063539, rs3774262 and rs1063539; all r2>0.80).
Coronary artery disease
Among the 11 SNPs, the minor allele of rs266729 was
significantly associated with higher odds of CAD after
adjusting for age and sex (P = 0.00095), and correctionDIPOQ with coronary artery disease
F OR (95% CI) P value
CAD Patients
0.338 1.64 (1.35 - 2.01) 0.00095*
0.423 1.18 (0.98 - 1.52) 0.113
0.147 0.82 (0.64 - 1.06) 0.126
0.131 0.94 (0.72 - 1.23) 0.670
0.398 1.04 (0.87 - 1.25) 0.572
0.226 0.87 (0.71 - 1.08) 0.217
0.238 0.83 (0.67 - 1.03) 0.102
0.421 1.07 (0.89 - 1.28) 0.482
0.265 0.85 (0.69 - 1.04) 0.129
0.302 1.06 (0.87 - 1.30) 0.543
0.183 0.83 (0.66 - 1.05) 0.116
alue that can pass multiple testing correction (P < 0.0086).
Table 4 Stepwise multivariate linear regression for
adiponectin level (ln-transformed)
Parameters β* P value
age 0.008 < 0.001
male gender - 0.181 < 0.001
BMI - 0.041 < 0.001
hypertension - 0.136 < 0.001
2-h post-OGTT glucose -0.011 0.044
HbA1c - 0.025 0.003
HDL cholesterol 0.191 < 0.001
R2 0.371
* Adjusted for age, sex, BMI, diabetes duration, current smoking, hypertension,
HbA1c, fasting glucose, 2-h post-OGTT glucose, triglyceride, HDL cholesterol,
and LDL cholesterol in the stepwise model.
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significant after further adjusting for BMI, diabetes dur-
ation, current smoking, hypertension, fasting glucose,
2-h post-OGTT glucose, HbA1c, triglyceride, HDL
cholesterol, LDL cholesterol [OR (95% confidence interval
(CI)) = 1.49 (1.10 - 2.16), P = 0.022] (Table 3). In a sepa-
rate analysis, similar results were obtained under the as-
sumption of dominant or recessive allelic effect (OR (95%
CI) = 1.56 (1.18 - 2.09), P = 0.002; OR (95%
CI) = 1.90 (1.19 - 3.01), P = 0.005 in full adjustment
model, respectively). In forward stepwise multivariate
logistic regression, this SNP was a significant inde-
pendent factor of CAD (Table 3). In this study, the 560
CAD patients and 550 control subjects could provide
>80% power (α= 0.05) to detect genetic effects with
allelic OR above 1.46 for rs266729.Plasma adiponectin level
The adiponectin level was negatively correlated with male
gender, BMI, hypertension, triglycerides, fasting glucose, 2-
h post-OGTT glucose, and HbA1c, and positively corre-
lated with age and HDL cholesterol (all P < 0.05), and was
not related to diabetes duration, current smoking, LDL
cholesterol (P > 0.05). In forward stepwise multivariate
linear regression, male gender, lower age, higher BMI,
hypertension, 2-h higher post-OGTT glucose, higher
HbA1c, and lower HDL cholesterol were independent fac-
tors associated with lower adiponectin level, explaining
37.1% variation in adiponectin level (Table 4). Therefore, in
all subsequent analysis of adiponectin level, all models were
adjusted for age, sex, BMI, hypertension, 2-h post-OGTT
glucose, HbA1c, and HDL cholesterol.Table 3 OR for the association between CAD and
rs266729 SNP in the ADIPOQ
Parameter OR (95% CI) * P value
AGE 1.12 (1.10 - 1.15) < 0.001
BMI 1.22 (1.17 - 1.27) < 0.001
diabetes duration 1.06 (1.03 - 1.10) 0.001
current smoking 1.46 (1.08 - 1.97) 0.014
2-h post-OGTT glucose 1.35 (1.23 – 1.47) < 0.001
HbA1c 1.38 (1.22 - 1.57) < 0.001
HDL cholesterol 0.32 (0.18 - 0.57) < 0.001
rs266729
G† 1.49 (1.10 - 2.16) 0.022
CG‡ 1.53 (1.08 - 1.92) 0.028
GG‡ 2.18 (1.32 - 3.46) < 0.001
† and ‡ OR are computed using major allele or major allele homozygotes as
the reference group, respectively. *Adjusted for age, sex, BMI, diabetes
duration, current smoking, hypertension, HbA1c, fasting glucose, 2-h post-
OGTT glucose, triglyceride, HDL cholesterol, and LDL cholesterol in stepwise
multivariate logistic regression model.Several genetic variants were significantly associated
with adiponectin level after adjusting for the above co-
variates (Figure 1). The minor alleles of rs266729 and
rs182052 were significantly associated with lower level
(β = −0.101, P < 0.0001 and β = −0.044, P = 0.0035 re-
spectively), whereas the minor alleles of rs1501299
were significantly associated with higher level (β =
0.073, P < 0.0001).
Haplotype analysis
Haplotypes were constructed using the rs266729, rs182052,
and rs1501299 as these SNPs showed significant association
with adiponectin level. There were five common haplotypes
with frequency >5%, namely, CGG (32.8%), CGT (15.6%),
CAG (19.4%), GAG (17.9%), and GGG (5.2%).
Consistent with the individual SNP analyses, a signifi-
cant association with CAD was observed for the
haplotypes. Figure 2A shows the maximum likelihood
estimates of the haplotypes in the combined case and
control subjects along with their score statistics for
association with CAD as computed by the HAPLO.
SCORE program [22]. Haplotype distributions were sig-
nificantly different in case and control subjects (global P =
0.0003). Haplotype CAG, which exactly corresponds to
the major allele of rs266729, was associated with
protection from CAD (P < 0.001), whereas haplotype
GAG, exactly corresponding to the minor allele of
rs266729, was associated with predisposition (P < 0.001).
Despite the low frequency of GGG haplotype, a predispos-
ing effect was also observed for this haplotype, and the P
value did reach significance (P < 0.001). When diplotypes
were assigned to each subject, there were seven common
diplotypes with frequency >5%, haplotypes GGG and
GAG combination were significantly associated with an
increased risk of CAD (Figure 2B). The ORs of CAD for
these genotypes compared with CAG/CAG homozygotes
ranged from 2.13 to 3.39. The ORs were lower and did
not differ significantly from 1.0 when haplotypes CGT
Figure 1 Associations of SNPs with adiponectin level. The bar shows the magnitude of β-coefficients in multivariate linear regression analysis
of adiponectin level (ln-transformed) after adjusting for age, sex, BMI, hypertension, 2-h post-OGTT glucose, HbA1c, and HDL cholesterol.
* P values that can pass multiple testing correction (P < 0.0086).
Figure 2 Haplotypes in the ADIPOQ locus and cardiovascular risk. A: Haplotype frequencies in Control subjects and CAD patients. Positive
and negative scores denote an association with increased and decreased risk of CAD, respectively. Haplotype-specific P values are reported along
with the global P value. B: OR of CAD associated with different haplotype combinations (diplotypes). OR are indicated by the squares and 95% CI
by the lines.
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(Figure 2B). We also noticed that CGG/CGT diplotype
had an increased risk for CAD, although the P value was
marginally significant (P = 0.053).Angiographical severity and extent of coronary
atherosclerosis
The association of genetic variants in the ADIPOQ gene
with the angiographical severity and extent in CAD
patients and control subjects was evaluated by investi-
gating Gensini and Sullivan Extent scores according to
adiponectin genotypes. Gensini score (ln-transformed)
increased significantly from the rs266729 genetype CC
over the CG to the GG (Data are expressed as geometric
mean (95% CI), 12.4 (11.6 - 13.2) vs. 22.2 (21.0 - 23.5)
and 34.1 (31.5 - 36.9), P < 0.001, respectively), and
Sullivan Extent score (ln-transformed) increased signifi-
cantly from the rs266729 genetype CC over the CG to
the GG (Data are expressed as geometric mean (95%
CI), 14.6 (12.5 - 15.1) vs. 25.4 (22.5 - 27.3) and 38.6
(33.8 - 41.7), P < 0.001, respectively) (Figure 3). More-
over, the minor G allele was significantly associated
with higher Gensini score (β = 0.139, P < 0.001) and
Sullivan Extent score (β = 0.107, P < 0.001) after
adjusting for age, sex, BMI, diabetes duration, current
smoking, hypertension, 2-h post-OGTT glucose,
HbA1c, triglyceride, HDL cholesterol, and LDL choles-
terol in stepwise multivariate linear regression model.
The association remained significant under the assump-
tion of dominant or recessive allelic effect even after
adjusting for the above covariates (Gensini score: β =
0.152, P < 0.001, β = 0.163, P < 0.001, respectively; Sulli-
van Extent score: β = 0.131, P < 0.001, β = 0.142, P <
0.001, respectively).Figure 3 Coronary artery disease severity by rs266729 genotype. CAD
Gensini score (P < 0.001) and (B) the unadjusted geometric mean of Sulliva
geometric mean.Discussion
In this study, we have demonstrated that three genetic
variants, namely rs266729 (−11377C>G), rs182052
(−10066G>A), and rs1501299 (+276G>T) are asso-
ciated with adiponectin level, with the effect being
stronger for rs266729 and rs1501299. The present
study also indicates the correlation between the variants
of rs266729 and angiographically-diagnosed CAD in type
2 diabetes in Chinese population, and this is the first in-
vestigation demonstrating that the minor allele of
rs266729 is associated with the angiographical severity
and extent of coronary atherosclerosis. This effect appears
to be due to allelic differences in ADIPOQ, which may in-
fluence the antiatherogenic effects of adiponectin on tar-
get tissues. These results confirm and extend the evidence
implicating adiponectin as a physiological modulator of
atherogenesis and point to variability in the ADIPOQ gene
as a key regulator of this effect.
Among these SNPs, rs266729 is located in the gene
promoter region, whereas rs182052 and rs1501299 are
located in the intron 1 and intron 2 region. When com-
pared with other previous studies, there seems to be
ethnic difference in the associations of genetic variants
with adiponectin level. In the Genetic Epidemiology of
Metabolic Syndrome Study, the SNPs most strongly
associated with adiponectin were rs3774261 and rs6773957
in ADIPOQ gene in Northern and Western European
populations [14]. In the Framingham Offspring Study [15],
the SNPs of rs17300539, rs822387 (which both are located
in promoter region), and rs6773957 (which is located in
3'-untranslated region) were associated with adiponectin
levels, which were not found in our subjects.
According to the Alibaba 2.1 program [23], a loss of a
Sp1-binding site and gain of a CCAAT/enhancer-binding
protein (C/EBP) β-binding site are resulted from theseverity is illustrated here as (A) the unadjusted geometric mean of
n Extent score (P < 0.001). The error bar shows the 95% CI of the
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two binding sites are involved in adipocyte differen-
tiation [24]. Previous study has demonstrated that the
first intron of the human ADIPOQ gene contains a gene
expression enhancer element, which responds to C/EBP
α, but not to C/EBP β [25]. Therefore, to investigate
whether this enhancer element could also respond to Sp1 is
of great interests.
While the effect of ADIPOQ variability on CAD risk
appears to be mediated by differences in gene expres-
sion, the identities of the sequence variants that are
responsible for this effect remain to be further investi-
gated. The observation that the five haplotypes fall into
more than two risk classes suggests the involvement of
multiple polymorphisms, either the tagging SNPs or va-
riants in linkage disequilibrium with them, interacting
with each other. It has been reported that the minor G
allele of SNP rs266729 alters DNA-binding activity, lead-
ing to lower basal and inducible promoter activity in
mouse 3 T3-L1 adipocytes [26]. Other findings also
reveal that this SNP destroys the binding site of
transcriptional stimulatory protein, Sp1 [27]. This might
be a reasonable explanation for the association between
rs266729 SNP and CAD.
ADIPOQ polymorphisms may affect cardiovascular risk
through various mechanisms involved in adiponectin.
Adiponectin suppresses endothelial adhesion molecule ex-
pression, vascular smooth muscle cell proliferation, and
macrophage-to-foam cell transformation as well as tumor
necrosis factor-alpha and interleukin-6 production by mac-
rophages in vitro [28,29]. It has been reported that the
adiponectin-knockout mice exhibits enhanced neointimal
thickening after vascular injury [30]. Administration of re-
combinant adenovirus expressing human adiponectin to
apoE-deficient animals causes a 30% reduction in the for-
mation of atherosclerotic lesions in the absence of any ef-
fects on metabolic traits [31]. These findings suggest that
adiponectin has a wide range of antiatherogenic property
and acts as an endogenous mediator of vascular and meta-
bolic diseases. In our study, CAD patients had lower
plasma adiponectin level than the control subjects, which is
aligned with the result from a recent meta-analysis [32].
Although rs266729 has been reported to be associated
with diabetes, severe forms of obesity, carotid intima media
thickness, and other cardiovascular risks [3,4,33-37], the
role of adiponectin gene rs266729 (−11377C>G) polymor-
phisms in angiographic CAD was seldom explored. In our
investigation, the presence of the G allele of the rs266729 is
strongly associated with an increased prevalence of coron-
ary heart disease. This is aligned with the findings by
Hoeffel et al. [16]. A recent meta-analysis also showed that
the associations between rs266729 in the ADIPOQ and car-
diovascular disease were significant [38]. But there are some
differences from Zhong’s study [39], it was reported thatrs266729 of the adiponectin gene was not associated with
CAD (OR =1.24, 95%CI: 0.91-1.69, p= 0.20) in a 435
Chinese population study, but female carriers of allele G at
rs266729 had a higher risk of CAD compared with allele C
carriers (OR = 1.30, 95% CI: 1.09-2.64, p = 0.02). Moreover,
it isn’t also consistent with Chen’s study [40], which re-
vealed that genetic polynmrphism in rs266729 was not as-
sociated with coronary artery disease in a 517 Chinese
subjects. However, we noticed that the major limitation of
the studies was the number of the patients. Several studies
arising from the HapMapII data such as the Wellcome
trust case control consortium reported required sample
sizes of several thousands even if the MAF is 0.5 and the
assumed OR larger than 1.5 and adjusted p of 10E-8
[41,42]. On the other hand, the association between the
−11377 C>G proximal promoter polymorphism and CAD
hasn’t also been detected in patients with type 2 diabetes in
Caucasian population [43]. There also seems to be ethnic
difference in the associations of genetic variants with CAD.
Interestingly, our data also reveal that the minor G allele of
SNP rs266729 is associated with the severity and extent of
coronary atherosclerosis when the angiographic extent was
evaluated by Gensini score and Sullivan Extent score in
Chinese type 2 diabetes. We found that the heterozygous
CG genotype and the homozygous GG genotype had
higher Gensini score and Sullivan Extent score, and this dif-
ference remained significantly even after controlling for co-
variates. Although the exact biological mechanism of this
association remains to be explored, our study provides
credible evidence that the rs266729 polymorphism may
contribute to the etiology of the severity of coronary
atherosclerosis and plays an important role in the athero-
sclerotic process.
The adiponectin rs1501299 G>T variant was positively
related with an increased risk of CAD, and the CAD pa-
tients had lower adiponectin levels which were not af-
fected by the different genotypes of rs1501299 in Gui’s
study [44]. However, there was an association between
rs1501299 G>T and adiponectin levels in our study. But
we should notice that only 35% of subjects in Gui’s study
have detected the adiponectin levels, it could reside in
the sample size not large enough to investigate this pre-
cise issue. The exact reasons were not clear, the differ-
ence of the study population may in part explain the
difference of the results. Enlarging the sample size and
performing a prospective study would make the conclu-
sions more convincing.
Study limitations
Some limitations of our study should be acknowledged.
As a potential limitation, population stratification may
influence the observed associations. However, our popu-
lation is racially homogeneous, with the whole of the
participants being Han. On the other hand, our study
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may not be necessarily applicable to other populations.
Another limitation is that the two groups had some dif-
ferences in the baseline characteristics, which may affect
the results. We have attempted to minimize the effect of
these differences by multivariate analysis. Moreover, it
must be emphasized that this was a cross-sectional
study, which might be susceptible to bias due to pos-
sible effects of genetic variants on survival. Thus, our
findings must be confirmed in prospective studies be-
fore ADIPOQ polymorphisms can be considered as
predictors of CAD in type 2 diabetes. Finally, Recep-
tors for adiponectin have been characterized that me-
diate effects of adiponectin in various tissues and may
have a higher risk of cardiovascular disease [45].
Advanced investigation should be conducted to dem-
onstrate whether the receptors for adiponectin, such as
ADIPOR1 and ADIPOR2, have an impact on the risk
of developing type 2 diabetes and CAD in a special
race.Conclusions
In conclusion, several genetic variants in the ADIPOQ
gene are associated with adiponectin level in this Chin-
ese population. Among these variants, a C to G allele
substitution of the rs266729 SNP is associated with a
significantly higher risk of CAD in type 2 diabetes, and
this SNP is also associated with the angiographical sever-
ity of coronary atherosclerosis. Our study has provided
further evidence for a role of adiponectin in the develop-
ment of CAD.
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